2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro

doi:10.1055/s-0034-1376151

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2014; 40(04): 407-412
DOI: 10.1055/s-0034-1376151

Editorial

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Authors

Emmanuel J. Favaloro

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Abstract

Volltext

Referenzen

References
1 Favaloro EJ. Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the closing issue for 2008. Semin Thromb Hemost 2008; 34: 693-696
2 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008; 34 (8) 703-707
3 Favaloro EJ. Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009; 35: 1-2
4 Favaloro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen Award for most popular article. Semin Thromb Hemost 2009; 35: 587-590
5 Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award winners. Semin Thromb Hemost 2010; 36: 469-470
6 Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. Semin Thromb Hemost 2010; 36 (7) 685-692
7 Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011; 37 (5) 431-439
8 Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012; 38: 425-432
9 Favaloro EJ. Eberhard F. Mammen award announcements. Semin Thromb Hemost 2013; 39: 567-574
10 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012; 38 (1) 47-54
11 Kenet G, Aronis S, Berkun Y , et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011; 37 (7) 802-809
12 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012; 38 (1) 102-113
13 Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost 2011; 37 (7) 737-744
14 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 2012; 38 (5) 454-462
15 Lyle CA, Bernard TJ, Goldenberg NA. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. Semin Thromb Hemost 2011; 37 (7) 786-793
16 Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012; 38 (1) 7-15
17 Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. Semin Thromb Hemost 2011; 37 (6) 640-652
18 Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. Semin Thromb Hemost 2012; 38 (2) 135-143
19 Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost 2011; 37 (7) 745-755
20 Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010; 36 (8) 807-818
21 Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. Semin Thromb Hemost 2012; 38 (1) 64-78
22 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: Part I—acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
23 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 673-682
24 Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost 2011; 37 (6) 621-630
25 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012; 38 (5) 483-496
26 Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012; 38 (1) 55-63
27 Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 2012; 38 (4) 305-321
28 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38 (1) 16-22
29 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012; 38 (2) 178-184
30 Favaloro EJ, Wong RC. The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. Semin Thromb Hemost 2012; 38 (4) 299-304
31 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38 (1) 79-94
32 Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012; 38 (2) 200-212
33 Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011; 37 (8) 929-945
34 Montagnana M, Favaloro EJ, Lippi G. Coffee intake and cardiovascular disease: virtue does not take center stage. Semin Thromb Hemost 2012; 38 (2) 164-177
35 Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 2012; 38 (5) 469-482
36 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
37 Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012; 38 (4) 348-352
38 Zoellner H. Dental infection and vascular disease. Semin Thromb Hemost 2011; 37 (3) 181-192
39 Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost 2011; 37 (3) 237-251
40 Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 2012; 38 (5) 447-453
41 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013; 39 (2) 117-126
42 Adams M. Tissue factor pathway inhibitor: new insights into an old inhibitor. Semin Thromb Hemost 2012; 38 (2) 129-134
43 Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012; 38 (4) 339-347
44 Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36 (6) 669-672
45 Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012; 38 (4) 333-338
46 De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost 2011; 37 (3) 226-236
47 Thom KE, Hanslik A, Male C. Anticoagulation in children undergoing cardiac surgery. Semin Thromb Hemost 2011; 37 (7) 826-833
48 Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 594-610
49 Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. Semin Thromb Hemost 2010; 36 (8) 881-887
50 Ranucci M, Baryshnikova E, Colella D. Monitoring prohemostatic treatment in bleeding patients. Semin Thromb Hemost 2012; 38 (3) 282-291
51 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (8) 709-733
52 Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost 2012; 38 (1) 31-37
53 Toriello HV. Thrombocytopenia-absent radius syndrome. Semin Thromb Hemost 2011; 37 (6) 707-712
54 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 632-641
55 Kuperman AA, Kenet G, Papadakis E, Brenner B. Intraventricular hemorrhage in preterm infants: coagulation perspectives. Semin Thromb Hemost 2011; 37 (7) 730-736
56 Heleen van Ommen C, Middeldorp S. Thrombophilia in childhood: to test or not to test. Semin Thromb Hemost 2011; 37 (7) 794-801
57 Darvish-Kazem S, Douketis JD. Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. Semin Thromb Hemost 2012; 38 (7) 652-660
58 Franchini M, Vescovi PP, Garofano M, Veneri D. Helicobacter pylori-associated idiopathic thrombocytopenic purpura: a narrative review. Semin Thromb Hemost 2012; 38 (5) 463-468
59 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29 (2) 125-130
60 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (1) 23-30
61 Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost 2010; 36 (1) 59-70
62 Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36 (8) 888-906
63 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31 (4) 381-392
64 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37 (3) 267-274
65 Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35 (4) 400-406
66 Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011; 37 (3) 280-297